These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16785511)

  • 1. Tumor escape mutants develop within an immune-privileged environment in the absence of T cell selection.
    Chen PW; Uno T; Ksander BR
    J Immunol; 2006 Jul; 177(1):162-8. PubMed ID: 16785511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Termination of immune privilege in the anterior chamber of the eye when tumor-infiltrating lymphocytes acquire cytolytic function.
    Ksander BR; Mammolenti MM; Streilein JW
    Transplantation; 1991 Jul; 52(1):128-33. PubMed ID: 1907041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
    Chen PW; Ksander BR
    Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction.
    Boonman ZF; van Mierlo GJ; Fransen MF; Franken KL; Offringa R; Melief CJ; Jager MJ; Toes RE
    J Immunol; 2004 Feb; 172(3):1567-74. PubMed ID: 14734736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege.
    Chen PW; Uno T; Ksander BR
    Exp Eye Res; 2006 Sep; 83(3):574-83. PubMed ID: 16643898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8+ T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-alpha-dependent mechanism.
    Dace DS; Chen PW; Niederkorn JY
    J Immunol; 2007 May; 178(10):6115-22. PubMed ID: 17475837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of infiltrating precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites.
    Ksander BR; Streilein JW
    J Immunol; 1990 Oct; 145(7):2057-63. PubMed ID: 1975822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infiltration and accumulation of precursor cytotoxic T-cells increase with time in progressively growing ocular tumors.
    Ksander BR; Bando Y; Acevedo J; Streilein JW
    Cancer Res; 1991 Jun; 51(12):3153-8. PubMed ID: 1904003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accumulation of immunosuppressive CD11b+ myeloid cells correlates with the failure to prevent tumor growth in the anterior chamber of the eye.
    McKenna KC; Kapp JA
    J Immunol; 2006 Aug; 177(3):1599-608. PubMed ID: 16849468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
    Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
    J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells.
    Walker PR; Calzascia T; Schnuriger V; Scamuffa N; Saas P; de Tribolet N; Dietrich PY
    J Immunol; 2000 Sep; 165(6):3128-35. PubMed ID: 10975826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloantigen presentation to the anterior chamber of the eye subverts specific in vitro cell-mediated immune responses.
    Whittum JA; Niederkorn JY; Streilein JW
    Transplantation; 1982 Oct; 34(4):190-5. PubMed ID: 6183804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space.
    Wenkel H; Chen PW; Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3202-8. PubMed ID: 10586943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye.
    Knisely TL; Niederkorn JY
    Cancer Immunol Immunother; 1990; 30(6):323-30. PubMed ID: 2302723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner.
    Dace DS; Chen PW; Alizadeh H; Niederkorn JY
    J Leukoc Biol; 2007 Feb; 81(2):421-9. PubMed ID: 17077163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nonclassical MHC class I molecule restricts CTL-mediated rejection of a syngeneic melanoma tumor.
    Chiang EY; Stroynowski I
    J Immunol; 2004 Oct; 173(7):4394-401. PubMed ID: 15383569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-leukocyte function-1 antibody treatment prevents the rejection of intraocular regressor tumors and their metastases.
    Li XY; Mayhew E; Niederkorn JY
    Curr Eye Res; 1995 Aug; 14(8):719-26. PubMed ID: 8529408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
    Manning TC; Rund LA; Gruber MM; Fallarino F; Gajewski TF; Kranz DM
    J Immunol; 1997 Nov; 159(10):4665-75. PubMed ID: 9366389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of TRAIL and IFN-gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye.
    Wang S; Boonman ZF; Li HC; He Y; Jager MJ; Toes RE; Niederkorn JY
    J Immunol; 2003 Sep; 171(6):2789-96. PubMed ID: 12960299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.